Prostate cancer (PCa) is the second most common male cancer worldwide and the fifth leading cause of death from cancer in men. Early detection and risk stratification is the most effective way to improve the survival of PCa patients. Current PCa biomarkers lack sufficient sensitivity and specificity to cancer. Metabolite biomarkers are evolving as a new diagnostic tool. This review is aimed to evaluate the potential of metabolite biomarkers for early detection, risk assessment, and monitoring of PCa. Of the 154 identified publications, 27 and 38 were original papers on urine and serum metabolomics, respectively. Nuclear magnetic resonance (NMR) is a promising method for measuring concentrations of metabolites in complex samples with good reproducibility, high sensitivity, and simple sample processing. Especially urine-based NMR metabolomics has the potential to be a cost-efficient method for the early detection of PCa, risk stratification, and monitoring treatment efficacy.
[1]Shanghai Univ Med & Hlth Sci, Zhoupu Hosp, Dept Urol, Shanghai 201318, Peoples R China.
[2]Tongji Univ, Sch Med, Dept Urol, Shanghai East Hosp, Shanghai 200120, Peoples R China.
[3]Zhejiang Univ, Sch Med, Dept Urol, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China.
[4]Univ Hosp Leipzig, Dept Urol, Liebigstr 20, D-04103 Leipzig, Germany.
[5]Univ Leipzig, Div Urol, Res Lab, Liebigstr 19, D-04103 Leipzig, Germany.
(8.0+极速模式)